Revolution Medicines, Inc. $RVMD Shares Acquired by S&CO Inc.

S&CO Inc. lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 56.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 22,171 shares of the company’s stock after purchasing an additional 8,000 shares during the quarter. S&CO Inc.’s holdings in Revolution Medicines were worth $1,035,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Nextech Invest Ltd. boosted its stake in Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the period. Bellevue Group AG lifted its holdings in shares of Revolution Medicines by 4.7% in the 2nd quarter. Bellevue Group AG now owns 4,579,300 shares of the company’s stock worth $168,472,000 after purchasing an additional 205,000 shares during the last quarter. Norges Bank acquired a new position in Revolution Medicines during the 2nd quarter valued at approximately $62,584,000. Westfield Capital Management Co. LP boosted its position in Revolution Medicines by 55.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,649,404 shares of the company’s stock valued at $60,682,000 after purchasing an additional 585,358 shares during the period. Finally, Vestal Point Capital LP bought a new position in Revolution Medicines during the 2nd quarter worth $44,148,000. Institutional investors own 94.34% of the company’s stock.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the completion of the sale, the chief financial officer directly owned 108,065 shares in the company, valued at $10,590,370. This represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark A. Goldsmith sold 15,394 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $1,182,567.08. Following the transaction, the insider directly owned 232,469 shares of the company’s stock, valued at approximately $17,858,268.58. The trade was a 6.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 213,792 shares of company stock worth $17,948,440 in the last three months. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Stock Down 0.8%

RVMD stock opened at $96.74 on Tuesday. The firm’s 50-day moving average is $92.93 and its two-hundred day moving average is $64.55. The company has a market capitalization of $18.70 billion, a price-to-earnings ratio of -18.71 and a beta of 1.00. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $124.49. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on RVMD. Royal Bank Of Canada started coverage on Revolution Medicines in a research note on Monday, November 3rd. They issued an “outperform” rating and a $77.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Mizuho started coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They set an “outperform” rating and a $90.00 target price for the company. Needham & Company LLC raised their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Raymond James Financial lifted their price target on Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a report on Friday, October 17th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $78.94.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.